News Lilly takes on Vertex in non-opioid pain with SiteOne buy Lilly buys SiteOne in a $1bn deal that would give it a rival to Vertex's approved painkiller Journavx, and a partnership on another programme.
News Vertanical's cannabis-based painkiller hits target in trials A cannabis-derived drug developed by Vertanical has shown efficacy in phase 3 for chronic back pain and could reach its first markets soon.
News Latigo raises $150m for non-opioid painkiller push Latigo has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million in a Series B.
News Digital health firm XRHealth hits the M&A trial again XRHealth has made its second acquisition in the space of a few months, buying digital therapeutics (DTx) company RealizedCare.
News Algiax non-opioid drug works in chronic neuropathic pain A GABA-targeting drug developed by German Biotech Algiax has shown proof of concept in a chronic neuropathic trial trial.
News Vertex bags FDA okay for its non-opioid pain drug Vertex gets FDA approval for its non-opioid pain drug suzetrigine, the first new class of pain medicine in the US in more than 20 years.
News RFK Jr formally backs thimerosal ban in US vaccines HHS Secretary Robert F Kennedy Jr has formally signed off on a recommendation to remove thimerosal from all flu vaccines in the US
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face